Table 1.

Benefits of anti-obesity drugs on obesity comorbidities*

Anti-obesity drugs	Comorbidities – main studies
Naltrexone/Bupropion	Depression ( McElroy SL et al. 2013 [177]) Type 2 diabetes (Hollander et al. 2013 [75]) Non-alcoholic fatty liver disease ( Bajaj HS et al. 2021 [115])
Liraglutide	Depression (Mansur RB et al. 2017 [183]) Type 2 diabetes (Madsbad S. et al. 2009 [80]) Non-alcoholic fatty liver disease (Armstrong MJ et al. 2016 [122]) Obstructive Sleep Apnea Syndrome (Blackman A et al. 2016 [144]) Cardiovascular diseases (Marso SP et al. 2016 [100])
Semaglutide	Type 2 diabetes (Sorli C et al. 2017 [85]) Cardiovascular diseases (Husain M et al. [107]) Non-alcoholic fatty liver disease (Newsome PN et al. 2021 [125])
Tirzepatide	Type 2 diabetes (Frias JP et al. 2018 [50]) Cardiovascular diseases (Dahl D et al. 2022 [97]) Non-alcoholic fatty liver disease (Gastaldelli A et al. 2022 [134])

^*Direct evidence deriving from clinical studies (i.e. RCT, observational studies etc.)